Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in Cancer

Retrieve available abstracts of 68 articles:
HTML format

Single Articles

    July 2021
  1. MACARTHUR KM, Baumann BC, Sobanko JF, Etzkorn JR, et al
    Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery.
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33651.
    PubMed     Abstract available

  2. SONDAK VK, Messina JL
    What's new in pediatric melanoma and Spitz tumors? Pretty much everything.
    Cancer. 2021 Jul 6. doi: 10.1002/cncr.33749.
    PubMed     Abstract available

    May 2021
    Cutaneous Melanoma Overdiagnosed, Researchers Find.
    Cancer. 2021;127:1547.

  4. TAYLOR LA, Eguchi MM, Reisch LM, Radick AC, et al
    Histopathologic synoptic reporting of invasive melanoma: How reliable are the data?
    Cancer. 2021 May 4. doi: 10.1002/cncr.33612.
    PubMed     Abstract available

    April 2021
  5. GOGEBAKAN KC, Mukherjee K, Berry EG, Sonmez K, et al
    Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries.
    Cancer. 2021 Apr 27. doi: 10.1002/cncr.33515.
    PubMed     Abstract available

  6. ESKANDER A, Marqueen KE, Edwards HA, Joshua AM, et al
    To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma.
    Cancer. 2021 Apr 12. doi: 10.1002/cncr.33499.
    PubMed     Abstract available

  7. BROMAN KK, Hughes T, Dossett L, Sun J, et al
    Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT-2).
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33483.
    PubMed     Abstract available

    Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned ... and still learning.
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33484.

    March 2021
  9. KEMPF E, Zalcman G, Lebbe C
    National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma?
    Cancer. 2021 Mar 31. doi: 10.1002/cncr.33495.

  10. CHRISTEN C, Belgodere L, Guillot B, Jumeau C, et al
    Access to innovation through the national early access program and clinical trials for patients with malignant melanoma.
    Cancer. 2021 Mar 25. doi: 10.1002/cncr.33492.
    PubMed     Abstract available

  11. BANDER ED, Yuan M, Carnevale JA, Reiner AS, et al
    Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Cancer. 2021 Mar 2. doi: 10.1002/cncr.33459.
    PubMed     Abstract available

    November 2020
  12. KARAPETYAN L, Yang X, Wang H, Sander CA, et al
    Indoor tanning exposure in association with multiple primary melanoma.
    Cancer. 2020 Nov 10. doi: 10.1002/cncr.33307.
    PubMed     Abstract available

    September 2020
  13. QIAN JM, Martin AM, Martin K, Hammoudeh L, et al
    Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases.
    Cancer. 2020 Sep 14. doi: 10.1002/cncr.33196.
    PubMed     Abstract available

  14. LI M, Sack JS, Rahma OE, Hodi FS, et al
    Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Cancer. 2020 Sep 5. doi: 10.1002/cncr.33165.
    PubMed     Abstract available

    August 2020
  15. KASHANI-SABET M, Miller JR 3rd, Lo S, Nosrati M, et al
    Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system.
    Cancer. 2020 Aug 11. doi: 10.1002/cncr.33088.
    PubMed     Abstract available

    July 2020
  16. PRINTZ C
    Research notes largest yearly decline in melanoma deaths.
    Cancer. 2020;126:3173.

    May 2020
  17. PATRINELY JR JR, Baker LX, Davis EJ, Song H, et al
    Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
    Cancer. 2020 May 28. doi: 10.1002/cncr.32984.
    PubMed     Abstract available

  18. ARORA M, Chen Y, Hageman L, Wu J, et al
    Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study.
    Cancer. 2020 May 15. doi: 10.1002/cncr.32941.
    PubMed     Abstract available

    March 2020
  19. MOLINA G, Kasumova GG, Qadan M, Boland GM, et al
    Use of immunotherapy and surgery for stage IV melanoma.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32817.
    PubMed     Abstract available

    January 2020
  20. WANG LX, Quach HT, Moodabigil NV, Davis EJ, et al
    Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
    Cancer. 2020;126:322-328.
    PubMed     Abstract available

    December 2019
    Considering adjuvant therapy for stage II melanoma.
    Cancer. 2019 Dec 23. doi: 10.1002/cncr.32585.
    PubMed     Abstract available

    November 2019
  22. ZHANG H, Zhu H, Deng G, Zito CR, et al
    PLEKHA5 regulates tumor growth in metastatic melanoma.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32611.
    PubMed     Abstract available

  23. COHEN JV, Wang N, Venur VA, Hadfield MJ, et al
    Neurologic complications of melanoma.
    Cancer. 2019 Nov 14. doi: 10.1002/cncr.32619.
    PubMed     Abstract available

  24. ABUDU B, Cook KA, Gershenwald JE, Cohen PR, et al
    Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32587.
    PubMed     Abstract available

    October 2019
  25. HOLBROOK K, Lutzky J, Davies MA, Davis JM, et al
    Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Cancer. 2019 Oct 28. doi: 10.1002/cncr.32547.
    PubMed     Abstract available

  26. KANDEL M, Dalle S, Bardet A, Allayous C, et al
    Quality-of-life assessment in French patients with metastatic melanoma in real life.
    Cancer. 2019 Oct 22. doi: 10.1002/cncr.32554.
    PubMed     Abstract available

  27. PIRES DA SILVA I, Lo S, Quek C, Gonzalez M, et al
    Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
    Cancer. 2019 Oct 4. doi: 10.1002/cncr.32522.
    PubMed     Abstract available

  28. BARTLETT EK, Flynn JR, Panageas KS, Ferraro RA, et al
    High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
    Cancer. 2019 Oct 4. doi: 10.1002/cncr.32506.
    PubMed     Abstract available

    August 2019
  29. SCHVARTSMAN G, Ma J, Bassett RL Jr, Haydu LE, et al
    Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Cancer. 2019 Aug 9. doi: 10.1002/cncr.32454.
    PubMed     Abstract available

  30. Erratum: Jeter JM, Bowles TL, Curiel-Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18-44.
    Cancer. 2019;125:2706.

    July 2019
  31. RULLI E, Legramandi L, Salvati L, Mandala M, et al
    The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32375.
    PubMed     Abstract available

    June 2019
  32. GROVER S, Srivastava A
    Lymphocytic colitis-like pattern of mucosal injury and the challenges in diagnosing cancer immunotherapy-related toxicity.
    Cancer. 2019;125:1768-1770.

    May 2019
  33. NAJJAR YG, Puligandla M, Lee SJ, Kirkwood JM, et al
    An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
    Cancer. 2019 May 8. doi: 10.1002/cncr.32162.
    PubMed     Abstract available

    March 2019
  34. KOFF JL, Waller EK
    Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?
    Cancer. 2019;125:838-842.
    PubMed     Abstract available

    January 2019
  35. GIBNEY GT, Atkins MB
    Choice of first-line therapy in metastatic melanoma.
    Cancer. 2019 Jan 29. doi: 10.1002/cncr.31774.

  36. OTT PA, Pavlick AC, Johnson DB, Hart LL, et al
    A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Cancer. 2019 Jan 28. doi: 10.1002/cncr.31892.
    PubMed     Abstract available

    December 2018
  37. APPENZELLER S, Gesierich A, Thiem A, Hufnagel A, et al
    The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31843.
    PubMed     Abstract available

  38. SAAB KR, Mooradian MJ, Wang DY, Chon J, et al
    Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31889.
    PubMed     Abstract available

    November 2018
  39. BHATTY M, Kato S, Piha-Paul SA, Naing A, et al
    Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies.
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31812.
    PubMed     Abstract available

    October 2018

  40. Older melanoma patients may respond better to anti-PD1 immunotherapy.
    Cancer. 2018;124:3961.

  41. TARHINI AA, Frankel P, Ruel C, Ernstoff MS, et al
    NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31734.
    PubMed     Abstract available

  42. JETER JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, et al
    Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials.
    Cancer. 2018 Oct 3. doi: 10.1002/cncr.31719.
    PubMed     Abstract available

    September 2018
  43. GOLDSTEIN AM, Stidd KC, Yang XR, Fraser MC, et al
    Pediatric Melanoma in Melanoma-Prone Families.
    Cancer. 2018 Sep 12. doi: 10.1002/cncr.31641.
    PubMed     Abstract available

    July 2018
  44. FAJE AT, Lawrence D, Flaherty K, Freedman C, et al
    High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31629.
    PubMed     Abstract available

    April 2018
  45. DAVIS EJ, Johnson DB, Sosman JA, Chandra S, et al
    Melanoma: What do all the mutations mean?
    Cancer. 2018 Apr 17. doi: 10.1002/cncr.31345.
    PubMed     Abstract available

    March 2018
  46. TSAI KK, Bollin KB, Patel SP
    Obstacles to improving outcomes in the treatment of uveal melanoma.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31284.
    PubMed     Abstract available

  47. PRINTZ C
    First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
    Cancer. 2018;124:1097-1098.

  48. LEHRER S, Rheinstein PH, Rosenzweig KE
    Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31262.

  49. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31261.

    October 2017
  50. MCWILLIAMS RR, Allred JB, Slostad JA, Katipamula R, et al
    NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31072.
    PubMed     Abstract available

  51. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31083.
    PubMed     Abstract available

  52. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Cancer. 2017 Oct 12. doi: 10.1002/cncr.30946.
    PubMed     Abstract available

    September 2017
  53. BENCI JL, Minn AJ, Vachani CC, Bach C, et al
    Survivorship care planning in skin cancer: An unbiased statistical approach to identifying patterns of care-plan use.
    Cancer. 2017 Sep 8. doi: 10.1002/cncr.30985.
    PubMed     Abstract available

    August 2017
  54. ROBIN TP, Jones BL, Gordon OM, Phan A, et al
    A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.
    Cancer. 2017;123:3040-3049.
    PubMed     Abstract available

    June 2017
  55. SZCZEPANIAK SLOANE RA, Gopalakrishnan V, Reddy SM, Zhang X, et al
    Interaction of molecular alterations with immune response in melanoma.
    Cancer. 2017;123.
    PubMed     Abstract available

  56. BYRNE EH, Fisher DE
    Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
    Cancer. 2017;123.
    PubMed     Abstract available

  57. WESTPHAL D, Glitza Oliva IC, Niessner H
    Molecular insights into melanoma brain metastases.
    Cancer. 2017;123.
    PubMed     Abstract available

  58. LIM SY, Menzies AM, Rizos H
    Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Cancer. 2017;123.
    PubMed     Abstract available

  59. PEREZ-GUIJARRO E, Day CP, Merlino G, Zaidi MR, et al
    Genetically engineered mouse models of melanoma.
    Cancer. 2017;123.
    PubMed     Abstract available

  60. REDDY BY, Miller DM, Tsao H
    Somatic driver mutations in melanoma.
    Cancer. 2017;123.
    PubMed     Abstract available

  61. BARUCH EN, Berg AL, Besser MJ, Schachter J, et al
    Adoptive T cell therapy: An overview of obstacles and opportunities.
    Cancer. 2017;123.
    PubMed     Abstract available

  62. JOHNSON DB, Sullivan RJ, Menzies AM
    Immune checkpoint inhibitors in challenging populations.
    Cancer. 2017;123:1904-1911.
    PubMed     Abstract available

    May 2017
  63. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
    External quality assurance in nongynecologic cytology: The Australasian experience.
    Cancer. 2017;125:349-361.
    PubMed     Abstract available

    March 2017
  64. KALINSKY K, Lee S, Rubin KM, Lawrence DP, et al
    A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30663.
    PubMed     Abstract available

    February 2017

  65. Some Europeans with melanoma lack access to new, lifesaving drugs.
    Cancer. 2017;123:543-544.

    December 2016
  66. HOU JY, Baptiste C, Hombalegowda RB, Tergas AI, et al
    Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30473.
    PubMed     Abstract available

  67. KIM DW, Haydu LE, Joon AY, Bassett RL Jr, et al
    Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.
    Cancer. 2016 Dec 2. doi: 10.1002/cncr.30463.
    PubMed     Abstract available

    October 2016
  68. CLARKE LE, Flake DD 2nd, Busam K, Cockerell C, et al
    An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
    Cancer. 2016 Oct 21. doi: 10.1002/cncr.30385.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.